domains / families / science / proteome-mr-drug-target

proteome-mr-drug-target

separate

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

When to use

• nominating or de-risking a drug target from plasma-proteome GWAS
• mimicking pharmacological inhibition via cis-pQTL instruments
• separating shared-causal from LD-confounded signal
• screening on-target adverse phenotypes pheWAS-style
• producing publication-grade STROBE-MR plus PP.H4 evidence

Skill page

Source